SCHEMBL10025535

SCHEMBL10025535

CN(C)CC1CNc2nc3ccc(OCCCN(C)Cc4ccccn4)cc3n2C1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.35
PDE3B Q13370 2/20 0.34
PDE3A Q14432 2/20 0.34
KDM4E B2RXH2 1/20 0.34
PPARG P37231 1/20 0.34
FGFR1 P11362 2/20 0.33
SRC P12931 2/20 0.33
HTR6 P50406 1/20 0.33
TLR7 Q9NYK1 3/20 0.32
HTR5A P47898 1/20 0.32
ACHE P22303 2/20 0.32
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32
KCNH2 Q12809 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
HRH1 P35367 1/20 0.31
CCR8 P51685 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10025545 0.90 HTR6 (0.31) PDE3BPDE3AKDM4EPPARGFGFR1
SCHEMBL10025537 0.88 NPC1 (0.35) KCNA5PDE3BPDE3AACHEDRD2
SCHEMBL10025466 0.87 FGFR1 (0.39) PDE3BPDE3AKDM4EPPARGFGFR1
SCHEMBL6743257 0.86 PPARG (0.32) PDE3BPDE3AKDM4EPPARGFGFR1
SCHEMBL10025540 0.86 PDE3B (0.33) PDE3BPDE3AKDM4EPPARGFGFR1
SCHEMBL10025542 0.85 MAPKAPK2 (0.36) PDE3BPDE3AKDM4EPPARGFGFR1
SCHEMBL10025539 0.85 PPARG (0.33) PDE3BPDE3AKDM4EPPARGFGFR1
SCHEMBL10025541 0.85 ATM (0.39) PDE3BPDE3AKDM4EPPARGFGFR1
SCHEMBL10025544 0.84 MAPKAPK2 (0.38) PDE3BPDE3AKDM4EPPARGTLR7
SCHEMBL10025543 0.83 TLR7 (0.34) PDE3BPDE3ATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339173-B2 Benzimidazoles and methods of using same UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2022-05-24 US disclosed
WO-2021055518-A1 BENZIMIDAZOLES AND METHODS OF USING SAME UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-03-25 WO disclosed
US-20210079008-A1 Benzimidazoles and Methods of Using Same UNIVERSISITY OF UTAH RESEARCH FOUNDATION 2021-03-18 US disclosed
US-8207173-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2012-06-26 US disclosed
US-8207173-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2012-06-26 US disclosed
US-20100130513-A1 BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS ISIS PHARMACEUTICALS, INC. (US) 2010-05-27 US disclosed
US-20100130513-A1 BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS ISIS PHARMACEUTICALS, INC. (US) 2010-05-27 US disclosed
US-7642265-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2010-01-05 US disclosed
US-7642265-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2010-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130513-A1 BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS ZC3HAV1, NXF1, ZC3HAV1L KCNA5 2007/4885PDE3B 2301/4885PDE3A 2534/4885
US-20210079008-A1 Benzimidazoles and Methods of Using Same HAVCR2, SNRPE, SARS1 KCNA5 3973/4885PDE3B 3631/4885PDE3A 4079/4885
US-11339173-B2 Benzimidazoles and methods of using same HAVCR2, SNRPE, SARS1 KCNA5 3973/4885PDE3B 3631/4885PDE3A 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.